PATENT CLAIM ANALYSIS

Application Number: 16335765
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-08
Patent Classification: ["546", "070000"]

Abstract:
A method for treating small cell lung cancer (SCLC). In the method, a therapeutically effective amount of a compound of Formula I: wherein R 1 , R 2  and R 3  have the definitions disclosed in the specification is administered alone or in combination with one or more anticancer agents, or surgery, radiation therapy, chemotherapy, and/or targeted therapy.

Claim (Index 8):
A method for treating small cell lung cancer (SCLC) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula I: wherein R 1  is hydrogen or \u2014C(\u2550O)NHR; wherein R is unsubstituted or substituted alkyl group, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted benzyl; R 2  is selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted benzyl; and R 3  is selected from the group consisting of hydrogen, unsubstituted or substituted alkyl group, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted benzyl, an acyl (R a CO), a methansulfonyl (Me 2 SO 2 ) and a toluenesulfonyl (MeC 6 H 4 SO 2 ); wherein R a  is unsubstituted or substituted alkyl group, unsubstituted or substituted alkenyl group, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted benzyl, or an enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, solvate or prodrug thereof in combination with a second anticancer agent, a surgical therapy, a radiation therapy, a chemotherapy, a targeted therapy, or combination thereof.

Metadata:
- Claim Count in Document: 49.0
- Percentile: 99.0
- Lexical Diversity: 1.33333
- Patent Class: 546.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13549572', '15745639', '13504943', '15309382', '11490438']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7503600285026782
- 35 USC 102 Novelty (BERT): 0.5445606985931214
- Combined Prediction Score: 0.7297800955117226
- Mean Citation Score: 272.06953000000004
- Max Citation Score: 401.5671
- Similarity Product: 268.5581179547667

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test